Extrait

We propose a multi-institutional phase II haplo-identical T cell replete BMT study in children with high-risk leukemias. The myeloablative conditioning regimen prescribed will be TBI-based for lymphoid leukemias and busulfan-based for myeloid leukemias. Our goal is to establish an easily exportable, inexpensive platform for haplotransplantation that has a safety profile equivalent to matched related and unrelated BMTs. The primary objective will be to estimate the incidence of 6-month non-relapse mortality, hypothesizing that NRM is < 18%.

Critère d'inclusion

• Myeloablative Conditioning,HLA-mismatched Bone Marrow Transplantation,Graft Survival,Transplantion, Bone Marrow

Liens

• ictrp
• nct